非流行区EBV相关鼻咽癌血浆EBV-DNA纵向评估:LEA研究
该研究回顾性分析了2012至2023年间一家三级中心收治的167例非流行区、非转移性、EBER阳性鼻咽癌患者,纵向监测血浆EBV-DNA并与无复发生存期关联。中位随访60个月,治疗前EBV-DNA检出率96%但无预测切点;治疗后及诱导化疗后EBV-DNA阴性提示更好预后。
要点
- 治疗前EBV-DNA检出率96%,但未找到预测RFS的切点。
- 治疗后EBV-DNA不可测与更好RFS相关,同样无切点。
- 随访EBV-DNA提前中位38天预警71%的复发。
核心结论
- 血浆EBV-DNA是非流行区鼻咽癌的有价值预后生物标志物,治疗前和治疗后不可测具有正向预后价值。
研究设计与样本
- 回顾性分析2012至2023年间一家三级中心收治的167例非流行区、非转移性、组织学确诊EBER阳性鼻咽癌患者。
- 血浆EBV-DNA在治疗前(T1)、治疗后早期(T2a,≤6周)和晚期(T2b,≤14周)、随访期间(T3)及诱导化疗后(T4,如适用)检测。
主要发现
- 中位随访60个月(范围9-134),中位年龄50岁(范围22-75),男性占72%,84%为III-IV期(TNM第8版)。
- 治疗前EBV-DNA在96%患者中可检出,可检出vs不可检出的中位RFS为43 vs 62个月,无预测切点。
- 治疗后EBV-DNA不可测与更好RFS相关,同样无切点。
- 随访EBV-DNA提前中位38天(范围11-365)预警71%的复发。
- 非复发患者中91%随访EBV-DNA持续阴性,孤立阳性 spikes 无预后意义;诱导化疗后EBV-DNA对复发的阴性预测值为92%。
临床怎么用
- 作者认为治疗后及诱导化疗后EBV-DNA不可测具有正向预后价值。
- 作者认为诱导化疗后EBV-DNA是最具信息量的时间点。
- 作者认为临床实践中应进行纵向EBV-DNA监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Plasma Epstein Barr Virus (EBV)-DNA is an established biomarker for endemic EBV-related nasopharyngeal carcinoma (NPC). Its relevance in non-endemic regions is less understood. This study longitudinally assessed plasma EBV-DNA (LEA study) throughout the curative management of non-endemic EBV-related NPC to evaluate its prognostic value. MATERIALS AND METHODS: Between 2012 and 2023, patients with non-endemic, non-metastatic, histologically confirmed EBER+ NPC treated at a tertiary center were retrospectively analyzed. Plasma EBV-DNA levels were measured at pre-treatment (T1), early (T2a, ≤6 weeks) and late (T2b, ≤14 weeks) post-treatment, during follow-up (T3), and after induction chemotherapy (T4), when applicable. EBV-DNA was analyzed for its association with recurrence-free survival (RFS). RESULTS: At a median follow-up of 60 months (range: 9-134), 167 patients were included. Median age was 50 years (range: 22-75), with 72 % male; 84 % had stage III-IV disease (TNM VIII Edition). Pre-treatment EBV-DNA was detected in 96 % of patients, with no predictive cut-off (median RFS: 43 vs. 62 months for detectable vs. undetectable EBV-DNA). Post-treatment undetectable EBV-DNA correlated with better RFS, also with no cut-off. Follow-up EBV-DNA anticipated recurrence in 71 % of cases by a median of 38 days (range: 11-365). Persistently negative follow-up EBV-DNA was observed in 91 % of non-recurrent patients; isolated positive spikes lacked prognostic significance. Post-induction chemotherapy EBV-DNA demonstrated a 92 % negative predictive value for recurrence. CONCLUSIONS: Plasma EBV-DNA is a valuable prognostic biomarker for non-endemic NPC. Pre- and post-treatment undetectable EBV-DNA holds a positive prognostic value. Post-induction EBV-DNA is the most informative timepoint. Longitudinal EBV-DNA monitoring is warranted in clinical practice.
引用
- Alfieri S, Romanò R, Marceglia S, et al. Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study. Eur J Cancer. 2025. PMID: 40729842. doi:10.1016/j.ejca.2025.115625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。